PIOGLITAZONE IN HEP C: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY
吡格列酮治疗丙型肝炎:一项随机、双盲、安慰剂对照研究
基本信息
- 批准号:7603782
- 负责人:
- 金额:$ 6.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-03-01 至 2007-09-16
- 项目状态:已结题
- 来源:
- 关键词:CicatrixCombined Modality TherapyComputer Retrieval of Information on Scientific Projects DatabaseDiabetes MellitusDisease ProgressionDouble-Blind MethodEvaluationFatty LiverFatty acid glycerol estersFibrosisFundingGrantHepatitis CHistologicInstitutionInsulin ResistanceInterferonsLinkLiverLiver diseasesPatientsPharmaceutical PreparationsPioglitazonePlacebosRandomizedResearchResearch PersonnelResourcesSourceStudy SubjectTakeda brand of pioglitazone hydrochlorideTestingUnited States Food and Drug AdministrationUnited States National Institutes of HealthViral hepatitisWeekimprovednon-alcoholic fatty liverplacebo controlled study
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
There have been several studies that link the presence of fatty liver in patients with viral hepatitis C and the amount of scarring or disease progression in the liver. This accumulation of fat in the liver may be due to insulin resistance. In this study, we would like to test whether patients treated with an FDA approved drug for diabetes, Pioglitazone (or Actos) will:
A. Help reduce insulin resistance, which has been shown to be a key factor in causing fatty liver in patients with non-alcoholic fatty liver disease.
B. Assess whether the amount of fat in the liver improves during drug treatment, which may improve the amount of fibrosis (or scarring) in the liver.
C. Discover if patients being treated with Actos along with the established combination therapy, Ribaviron and Interferon, will respond better overall, to treatment for viral hepatitis C.
We plan to conduct a double-blind, placebo controlled study where the subject will undergo the normal 48 weeks of treatment for hepatitis C, in addition to the study medication (pioglitazone or placebo) with histologic evaluation of the liver before treatment and at the end of 48 weeks of therapy in the study in order to assess histologic improvement.
'
这个子项目是许多研究子项目中的一个
由NIH/NCRR资助的中心赠款提供的资源。子项目和
研究者(PI)可能从另一个NIH来源获得了主要资金,
因此可以在其他CRISP条目中表示。所列机构为
研究中心,而研究中心不一定是研究者所在的机构。
有几项研究将丙型肝炎患者脂肪肝的存在与肝脏中瘢痕形成或疾病进展的数量联系起来。这种脂肪在肝脏中的积累可能是由于胰岛素抵抗。在这项研究中,我们想测试接受FDA批准的糖尿病药物吡格列酮(或Actos)治疗的患者是否会:
A. 帮助减少胰岛素抵抗,这已被证明是导致非酒精性脂肪肝患者脂肪肝的关键因素。
B。 评估药物治疗期间肝脏中的脂肪量是否有所改善,这可能会改善肝脏中的纤维化(或瘢痕形成)量。
C. 发现如果患者正在接受艾可拓沿着与已建立的联合治疗,利巴韦林和干扰素,将更好地整体响应,治疗丙型病毒性肝炎。
我们计划进行一项双盲、安慰剂对照研究,其中受试者将接受正常的48周丙型肝炎治疗,以及研究药物(吡格列酮或安慰剂)治疗,并在研究治疗前和48周治疗结束时进行肝脏组织学评价,以评估组织学改善。
'
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HARI S CONJEEVARAM其他文献
HARI S CONJEEVARAM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HARI S CONJEEVARAM', 18)}}的其他基金
Effects of recombinant human leptin in nonalcoholic fatty liver disease (NAFLD)
重组人瘦素对非酒精性脂肪肝(NAFLD)的影响
- 批准号:
8039717 - 财政年份:2011
- 资助金额:
$ 6.39万 - 项目类别:
Effects of recombinant human leptin in nonalcoholic fatty liver disease (NAFLD)
重组人瘦素对非酒精性脂肪肝(NAFLD)的影响
- 批准号:
8220799 - 财政年份:2011
- 资助金额:
$ 6.39万 - 项目类别:
Effects of recombinant human leptin in nonalcoholic fatty liver disease (NAFLD)
重组人瘦素对非酒精性脂肪肝(NAFLD)的影响
- 批准号:
8814209 - 财政年份:2011
- 资助金额:
$ 6.39万 - 项目类别:
Effects of recombinant human leptin in nonalcoholic fatty liver disease (NAFLD)
重组人瘦素对非酒精性脂肪肝(NAFLD)的影响
- 批准号:
8448125 - 财政年份:2011
- 资助金额:
$ 6.39万 - 项目类别:
Effects of recombinant human leptin in nonalcoholic fatty liver disease (NAFLD)
重组人瘦素对非酒精性脂肪肝(NAFLD)的影响
- 批准号:
8600674 - 财政年份:2011
- 资助金额:
$ 6.39万 - 项目类别:
FENOFIBRATE FOR TREATMENT OF NASH: A RANDOM, DOUBLE BLIND, PLACEBO-CTRLD STUDY
非诺贝特治疗纳什:一项随机、双盲、安慰剂对照研究
- 批准号:
7603761 - 财政年份:2007
- 资助金额:
$ 6.39万 - 项目类别:
Fenofibrate for the treatment of patients with NASH
非诺贝特用于治疗 NASH 患者
- 批准号:
7178464 - 财政年份:2006
- 资助金额:
$ 6.39万 - 项目类别:
Fenofibrate for the treatment of patients with NASH
非诺贝特用于治疗 NASH 患者
- 批准号:
7032512 - 财政年份:2006
- 资助金额:
$ 6.39万 - 项目类别:
PIOGLITAZONE IN HEPATITIS C: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUD
吡格列酮治疗丙型肝炎:随机、双盲、安慰剂对照研究
- 批准号:
7376622 - 财政年份:2006
- 资助金额:
$ 6.39万 - 项目类别:
FENOFIBRATE FOR TREATMENT OF NASH: A RANDOM, DOUBLE BLIND, PLACEBO-CTRLD STUDY
非诺贝特治疗纳什:一项随机、双盲、安慰剂对照研究
- 批准号:
7376592 - 财政年份:2006
- 资助金额:
$ 6.39万 - 项目类别:
相似海外基金
Construction of the nursing practice model for accepting combined modality therapy for esophageal cancer to get the feeling of "Expectation for the recovery".
构建食管癌接受综合治疗获得“期待康复”感受的护理实践模式。
- 批准号:
26463339 - 财政年份:2014
- 资助金额:
$ 6.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Assessment of IFN-alpha activated BID gene/radiation combined modality therapy for human cancer stem cells
IFN-α激活BID基因/放射联合疗法对人类癌症干细胞的评估
- 批准号:
26461899 - 财政年份:2014
- 资助金额:
$ 6.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Basic study on combined modality therapy for advanced lung cancer harboring activated EGFR gene mutation
EGFR基因突变晚期肺癌联合治疗的基础研究
- 批准号:
25670399 - 财政年份:2013
- 资助金额:
$ 6.39万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Combined modality therapy targeting HPV oncogene for head and neck cancer
针对头颈癌 HPV 癌基因的联合疗法
- 批准号:
25462683 - 财政年份:2013
- 资助金额:
$ 6.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Assessment of immune-activated BID gene-radiation combined modality therapy
免疫激活 BID 基因放射联合治疗的评估
- 批准号:
23791456 - 财政年份:2011
- 资助金额:
$ 6.39万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
A PHASE II TRIAL OF COMBINED MODALITY THERAPY PLUS CETUXIMAB IN HIV-ASSOCIATED A
联合疗法加西妥昔单抗治疗 HIV 相关 A 患者的 II 期试验
- 批准号:
8167098 - 财政年份:2009
- 资助金额:
$ 6.39万 - 项目类别:
Early prediction of response to combined modality therapy by functional imaging
通过功能成像早期预测联合治疗的反应
- 批准号:
7324599 - 财政年份:2007
- 资助金额:
$ 6.39万 - 项目类别:
Early prediction of response to combined modality therapy by functional imaging
通过功能成像早期预测联合治疗的反应
- 批准号:
7487447 - 财政年份:2007
- 资助金额:
$ 6.39万 - 项目类别:
Novel combined modality therapy with radiotherapy and immunotherapy for the treatment of cancer
治疗癌症的放射疗法和免疫疗法的新型联合疗法
- 批准号:
19390314 - 财政年份:2007
- 资助金额:
$ 6.39万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
RM 98-1: Combined Modality Therapy For Locally Advanced Non-Small Cell Lung Ca
RM 98-1:局部晚期非小细胞肺钙的联合治疗
- 批准号:
7043972 - 财政年份:2003
- 资助金额:
$ 6.39万 - 项目类别: